Clinical trials: Obsessive-compulsive Disorder
Obsessive Compulsive Disorder
Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents
This study is to verify the efficacy of fluvoxamine maleate given for 10 weeks in treatment of children and adolescents with obsessive-compulsive disorder
- Trial name
- NCT00352768
- Testing
- Fluvoxamine maleate
- Where
- 11 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Solvay Pharmaceuticals
Obsessive Compulsive Disorder
Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.
- Trial name
- NCT00254735
- Testing
- quetiapine fumarate, SSRI/Clomipramine
- Where
- 2 sites in Germany
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Obsessive-Compulsive Disorder
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive disorder (OCD) who had an inadequate response to selective serotonin reuptake…
- Trial name
- NCT03299166
- Testing
- Troriluzole
- Where
- 57 sites in United States
- Volunteers
- 426 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Obsessive Compulsive Disorder
Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD)
The purpose of this study is to investigate the effect of NPL-2003 on the symptoms of Obsessive Compulsive Disorder (OCD) in an adolescent population.
- Trial name
- NCT00515255
- Testing
- Minocycline
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Neuropharm
Obsessive-compulsive Disorder
Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder
This study is to assess the efficacy and safety of two doses of ondansetron (0.5 mg and 0.75 mg) relative to placebo when administered twice daily as adjunctive therapy for adult patients with Obsessive-Compulsive Disorder (OCD)…
- Trial name
- NCT01275248
- Testing
- Ondansetron
- Where
- 32 sites in United States, Mexico
- Volunteers
- 130 people
- Sponsor
- Transcept Pharmaceuticals
Trichotillomania
Feasibility Study for Treating Trichotillomania With Wearable Device and App System
Trichotillomania is characterized by recurrent hair pulling resulting in hair loss causing significant distress and impairment which persists despite repeated attempts to stop.
- Trial name
- NCT04241120
- Testing
- Device and app system designed for participant to self-administer Habit Reversal Training, Reminder bracelet control condition
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- HabitAware Inc.
Medication-refractory Obsessive Compulsive Disorder (OCD)
ExAblate Treatment of Medication Refractory Obsessive Compulsive Disorder
The goal of this prospective, non-randomized, single-arm, single site, feasibility study is to develop and collect data to evaluate the safety and initial effectiveness of this treatment using this ExAblate transcranial System in…
- Trial name
- NCT01986296
- Testing
- ExAblate Transcranial MRgFUS System
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- InSightec
Obsessive Compulsive Disorder
Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF)
The purpose of the study is to monitor the safety and performance of Reclaim® Deep Brain Stimulation (DBS) Therapy in patients with chronic, severe, treatment-resistant Obsessive Compulsive Disorder.
- Trial name
- NCT01135745
- Testing
- Reclaim® Deep Brain Stimulation
- Where
- 8 sites in Belgium, Germany and 5 more
- Volunteers
- 32 people
- Sponsor
- MedtronicNeuro
Trichotillomania
Technology Assisted Treatment for Trichotillomania
The investigators are testing two digital health interventions for trichotillomania (TTM), via a randomized trial design.
- Trial name
- NCT05118633
- Testing
- Keen2 bracelet, Reminder bracelet, Keen2 app
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- HabitAware Inc.
Obsessive-compulsive Disorders and Symptoms, Obsessive-Compulsive Disorder
An ERP-based Mobile Intervention as an Adjunctive Treatment for OCD
The objective of this feasibility study is to evaluate the feasibility, acceptability, and potential usefulness of the investigational device, a mobile software application (app) (OC Free) for treatment of OCD (contamination…
- Trial name
- NCT05166707
- Testing
- BIXINK OC Free
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BIXINK Therapeutics Co., Ltd.
Obsessive-Compulsive Disorder
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Obsessive-Compulsive Disorder
The purpose of this clinical study is To verify the long term effectiveness and safety of a bilateral deep brain stimulation (DBS) produced by Beijing PINS Medical Co., Ltd.
- Trial name
- NCT02253472
- Testing
- Deep Brain Stimulation
- Volunteers
- 30 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Autism Spectrum Disorder, Depression - Major Depressive Disorder
Mental Health, Intellectual and Neurodevelopmental Disorder Detection With Artificial Intelligence Models
This study investigates whether AI-driven analysis of speech can accurately predict clinical diagnoses and assess risk for various mental or behavioral health conditions, including attention-deficit/hyperactivity disorder (ADHD)…
- Conditions
- Autism Spectrum Disorder, Depression - Major Depressive Disorder, Anxiety, Generalized, Bipolar Disorder (BD)
- Trial name
- MINDAIM (NCT06792175)
- Testing
- Solicue Machine Learning Models, Mercuria Machine Learning Models
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Psyrin Inc.
Depression, Anxiety
Focused Ultrasound for Behavioral Health
This is a double-blind, within-participant crossover, multi-site dose-finding study evaluating the safety, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound (LIFU) stimulation using the ATTN201…
- Conditions
- Depression, Anxiety, Obsessive Compulsive Disorder (OCD)
- Trial name
- VANTUS (NCT07851038)
- Testing
- ATTN201 head-worn focused ultrasound
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Attune Neurosciences Inc
Obsessive-Compulsive Disorder
Child and Adolescent OCD Outcomes From Exposure and Response Prevention Video Teletherapy Treatment
This is a naturalistic, observational study of children and adolescents with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy.
- Trial name
- NCT06466447
- Testing
- Exposure and response prevention therapy
- Where
- United States
- Volunteers
- 2,173 people
- Sponsor
- NOCD
Obsessive-Compulsive Disorder
Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors
3 groups of subjects (healthy controls, OCD subjects and stimulant-dependent subjects) will receive pramipexole (1.5 mg, single dose), amisulpride (400 mg, single dose) or placebo in a cross-over, double-blind, placebo-controlled…
- Trial name
- NCT00471588
- Testing
- Pramipexole, Amisulpride
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
The purpose of this study is to determine whether AFQ056 as an add on therapy to SSRIs can have beneficial effects by reducing the total score of Y-BOCS (Yale and Brown Obsessive Compulsive Scale) in OCD patients resistant to…
- Trial name
- NCT01813019
- Testing
- AFQ056
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Obsessive-Compulsive Disorder
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
- Trial name
- NCT04641143
- Testing
- Troriluzole
- Where
- 73 sites in United States
- Volunteers
- 456 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Posttraumatic Stress Disorder (PTSD), Avoidant Personality Disorder
Effectiveness of PTSD-treatment Compared to Integrated PTSD-PD-treatment in Adult Patients With Comorbid PTSD and CPD
The goal of PROSPER-C is to study effectiveness of ImRs compared to integrated SFT-ImRs in treatment-seeking, adult patients with comorbid PTSD and Cluster C Personality Disorder (CPD).
- Conditions
- Posttraumatic Stress Disorder (PTSD), Avoidant Personality Disorder, Dependent Personality Disorder, Obsessive Compulsive Personality Disorder
- Trial name
- PROSPER-C (NCT03833531)
- Testing
- ImRS, SFT
- Where
- Netherlands
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Arkin
Post-traumatic Stress Disorder (PTSD)
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
- Trial name
- NCT05189977
- Testing
- Propranolol, Prazosin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
This study will evaluate the use of intravenous immunoglobulins (IVIG) at a dose of 1g/Kg/body weight given every three weeks for 6 infusions in pediatric subjects ages 4 - 16 years with moderate to severe PANS.
- Trial name
- PANS (NCT03348618)
- Testing
- IVIG
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- IMMUNOe Research Centers